The aims of treatment of chronic hepatitis B are to achieve sustained suppression of HBV replication and remission of liver disease. The ultimate goal is to prevent cirrhosis, hepatic failure and HCC. A total 42 patients with chronic hepatitis B (include: 19 HBeAg(+), 23 HBeAg(-) received Pegasys180 ug one weekly/48 weeks. The resuls showed that: after 48 weeks follow-up, the percentage of patients with normalization AST, ALT levels is 68,4 percent and 63,2 percent; HBeAg seroconversion: 31,6 percent; serum HBV-DNA levels to undetectable(69 copies/ml): 31,6 percent (HBeAg(-) patients: 69,9 percent). The drug was found to have some adverse effects: pyrexia (73,9 percent); fatigue (90,4 percent); headache (83,3 percent); myalgia and arthralgia (76,2 percent). This adverse effects to occupe in first tree time injections, especially first time and to decrease in during therapy. The incidence of decreased appetite, alopecia, dizziness, pruritus, rash was lower and to late appear. About 10 percent patients had anaemia, aleukemia, trombopenia.
- Đăng nhập để gửi ý kiến